

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

HUMAN VITRONECTIN (N-TRUNCATED, C-6HIS) PROTEIN

目录: 12046

产品名称: Human Vitronectin (N-Truncated

规格: 10 μg, 50 μg and 100 μg

基因符号: Complement S-protein;epibolin;Serum Spreading

Factor; Serum-spreading factor; Somatomedin B; S-

protein; V75; Vitronectin; VN; VNT; VTN

Target: Vitronectin

UNIPROT ID: AAH05046.1

描述: Recombinant Human Vitronectin is produced by our Mammalian expression system and the target gene encoding Val62-Leu478 is expressed with a 6His tag at the C-terminus.

背景: Vitronectin, also known as VTN, is a large glycoprotein found in blood and the extracellular matrix (ECM). Vitronectin is a plasma glycoprotein implicated as a regulator of diverse physiological process, including blood coagulation, fibrinolysis, pericellular proteolysis, complement dependent immune responses, and cell attachment and spreading. Blocking of Hic(a member of the pneumococcal surface protein C (PspC) family) by specific antiserum or genetic deletion significantly reduced pneumococcal binding to soluble and immobilised vitronectin and to Factor H, respectively. In addition, Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.

Species/Host: HEK293

Molecular Weight: 48.3 KDa

Molecular Characterization: Not available

纯化:: Greater than 90% as determined by reducing SDS-PAGE.

Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization.

储存和运输: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010




Figure 1. Greater than 95% as determined by reducing SDS-PAGE.